Pieris Pharmaceuticals, which is developing a therapy for functional iron deficiency in anemic patients, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering.
Pieris Pharmaceuticals currently trades on the OTCQB under the symbol PIRS with a market cap of $90 million.
The Freising-Weihenstephan, Germany-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol PIRS. Oppenheimer & Co. and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
